Effectiveness of a closed-loop control system and a virtual educational camp for children and adolescents with type 1 diabetes: A prospective, multicentre, real-life study.
CSII
continuous glucose monitoring
glycaemic control
insulin pump therapy
observational study
type 1 diabetes
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
01
07
2021
received:
17
05
2021
accepted:
01
07
2021
pubmed:
7
7
2021
medline:
21
10
2021
entrez:
6
7
2021
Statut:
ppublish
Résumé
To evaluate the impact of a virtual educational camp (vEC) on glucose control in children and adolescents with type 1 diabetes using a closed-loop control (CLC) system. This was a prospective multicentre study of children and adolescents with type 1 diabetes using the Tandem Basal-IQ system. Insulin pumps were upgraded to Control-IQ, and children and their parents participated in a 3-day multidisciplinary vEC. Clinical data, glucose metrics and HbA1c were evaluated over the 12 weeks prior to the Control-IQ update and over the 12 weeks after the vEC. Forty-three children and adolescents (aged 7-16 years) with type 1 diabetes and their families participated in the vEC. The median percentage of time in target range (70-180 mg/dL; TIR) increased from 64% (interquartile range [IQR] 56%-73%) with Basal-IQ to 76% (IQR 71%-81%) with Control-IQ (P < .001). After the vEC, more than 75% of participants achieved a TIR of more than 70%. The percentage of time between 180 and 250 mg/dL and above 250 mg/dL decreased by 5% (P < .01) and 6% (P < .01), respectively, while the time between 70 and 54 mg/dL and below 54 mg/dL remained low and unaltered. HbA1c decreased by 0.5% (P < .01). There were no episodes of diabetic ketoacidosis or severe hypoglycaemia. In this study of children managing their diabetes in a real-world setting, more than 75% of children who participated in a vEC after starting a CLC system could obtain and maintain a TIR of more than 70%. The vEC was feasible and resulted in a significant and persistent improvement in TIR in children and adolescents with type 1 diabetes.
Substances chimiques
Blood Glucose
0
Hypoglycemic Agents
0
Insulin
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2484-2491Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Cherubini V, Bonfanti R, Casertano A, et al. Time in range in children with type 1 diabetes using treatment strategies based on nonautomated insulin delivery systems in the real world. Diabetes Technol Ther. 2020;22(7):509-515.
Breton MD, Kanapka LG, Beck RW, et al. A randomized trial of closed-loop control in children with type 1 diabetes. N Engl J Med. 2020;383(9):836-845.
Alcantara-Aragon V. Improving patients self-care using diabetes technologies. Ther Adv Endocrinol Metab. 2019;10:2042018818824215.
Messer LH, Berget C, Ernst A, Towers L, Slover RH, Forlenza GP. Initiating hybrid closed loop: a program evaluation of an educator-led control-IQ follow-up at a large pediatric clinic. Pediatr Diabetes. 2021;22:586-593.
Scaramuzza A, Cavalli C, Rabbone I. Control-IQ technology enhanced by educative path in diabetes children. Diabetes Res Clin Pract. 2020;169:108525.
Scaramuzza AE, Arnaldi C, Cherubini V, et al. Recommendations for the use of sensor-augmented pumps with predictive low-glucose suspend features in children: the importance of education. Pediatr Diabetes. 2017;18(8):883-889.
Berget C, Messer LH, Vigers T, et al. Six months of hybrid closed loop in the real-world: an evaluation of children and young adults using the 670G system. Pediatr Diabetes. 2020;21(2):310-318.
Dovc K, Boughton C, Tauschmann M, et al. Young children have higher variability of insulin requirements: observations during hybrid closed-loop insulin delivery. Diabetes Care. 2019;42:1344-1347.
Pinsker JE, Muller L, Constantin A, et al. Real-world patient-reported outcomes and glycemic results with initiation of control-IQ technology. Diabetes Technol Ther. 2021;23(2):120-127.
Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593-1603.
Breton MD, Kovatchev BP. One year real-world use of the control-IQ advanced hybrid closed-loop technology [published online ahead of print April 21, 2021]. Diabetes Technol Ther. 2021. https://doi.org/10.1089/dia.2021.0097
Forlenza GP, Ekhlaspour L, Breton M, et al. Successful at-home use of the tandem control-IQ artificial pancreas system in young children during a randomized controlled trial. Diabetes Technol Ther. 2019;21(4):159-169.
Kanapka LG, Wadwa RP, Breton MD, et al. Extended use of the control-IQ closed-loop control system in children with type 1 diabetes. Diabetes Care. 2021;44(2):473-478.
Bergenstal RM, Nimri R, Beck RW, et al. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet. 2021;397(10270):208-219.
Collyns OJ, Meier RA, Betts ZL, et al. Improved glycemic outcomes with Medtronic MiniMed advanced hybrid closed-loop delivery: results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes. Diabetes Care. 2021;44(4):969-975.
Brown SA, Kovatchev BP, Raghinaru D, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. 2019;381(18):1707-1717.